RESUMEN
OBJECTIVE: To develop and validate a sensitive and rapid ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of enasidenib in rat plasma and to investigate the effect of Xiao-ai-ping injection (XAPI) on the pharmacokinetics of enasidenib in rats. METHODS: The rat plasma was precipitated with acetonitrile, enasidenib and internal standard (IS) were separated on an Acquity UPLC BEH C18 column, and acetonitrile and 0.1% formic acid were used as the mobile phase in gradient mode. Enasidenib and IS were monitored and detected by multiple reaction monitoring (MRM) using tandem mass spectrometry in positive ion mode. 12 Sprague-Dawley (SD) rats were randomly divided into control group (group A) and experimental group (group B), 6 rats in each group. Group B was intramuscularly injected with XAPI (0.3 mL/kg) every morning, 7 days in a row. Group A was intramuscularly injected with normal saline, 7 days in a row. On the seventh day, enasidenib (10 mg/kg) was given to both groups 30 min after injection of normal saline (group A) or XAPI (group B), and the blood was collected at different time points such as 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 h. The concentration of enasidenib was detected by UPLC-MS/MS, and the main parameters of pharmacokinetic of enasidenib were calculated using the DAS 2.0 software. RESULTS: Under the current experimental conditions, this UPLC method showed good linearity in the detection of enasidenib. Interday and intraday precision did not exceed 10%, the range of accuracy values were from -1.43% to 2.76%. The results of matrix effect, extraction recovery, and stability met the requirements of FDA approval guidelines of bioanalytical method validation. The C max of enasidenib in the group A and the group B was (458.87 ± 136.02) ng/mL and (661.47 ± 107.32) ng/mL, t 1/2 was (7.74 ± 0.91) h and (8.64 ± 0.42) h, AUC(0 - t) was (4067.24 ± 1214.36) ng·h/mL and (5645.40 ± 1046.30) ng·h/mL, AUC(0 - ∞) was (4125.79 ± 1235.91) ng·h/mL and (5759.61 ± 1078.59) ng·h/mL, respectively. The C max of enasidenib in group B was 44.15% higher than that in group A, and the AUC(0 - t) and AUC(0 - ∞) of enasidenib in group B were 38.80% and 39.60% higher than that in group A, respectively, and the t 1/2 was prolonged from 7.74 h to 8.64 h. CONCLUSION: An UPLC-MS/MS method for the determination of enasidenib in rat plasma was established. XAPI can inhibit the metabolism of enasidenib and increase the concentration of enasidenib in rats. It is suggested that when XAPI was combined with enasidenib, the herb-drug interaction and adverse reactions should be paid attention to, and the dosage should be adjusted if necessary.
Asunto(s)
Aminopiridinas , Medicamentos Herbarios Chinos , Interacciones de Hierba-Droga , Triazinas , Aminopiridinas/farmacocinética , Aminopiridinas/farmacología , Animales , Cromatografía Líquida de Alta Presión , Medicamentos Herbarios Chinos/farmacocinética , Medicamentos Herbarios Chinos/farmacología , Masculino , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Triazinas/farmacocinética , Triazinas/farmacologíaRESUMEN
Imeglimin is a novel oral antidiabetic drug for treatment of type 2 diabetes that targets mitochondrial bioenergetics. Its pharmacokinetics absorption characteristics, metabolism, distribution, and elimination were assessed through several in vitro and in vivo experiments in both animals and humans. Its potential to induce drug-drug interactions was also extensively assessed. Imeglimin is a small cationic compound with an intermediate intestinal permeability. Its absorption mechanism involves an active transport process in addition to passive paracellular absorption. Absorption was good (50%-80%) in vivo across several species but decreased with increasing dose, probably because of saturation of active transport. After absorption, imeglimin was rapidly and largely distributed to internal organs. Plasma protein binding was low, which can explain the rapid distribution to organs observed in all species. In animals and humans, imeglimin was largely excreted unchanged in urine, indicating a low extent of metabolism. Unchanged drug was the main circulating entity in plasma, and none of the identified metabolites were unique to human. Imeglimin renal clearance was higher than creatinine clearance, indicating that it was actively secreted into urine. There was no evidence that it had the potential to cause cytochrome P450 inhibition or induction. It was shown to be a substrate of organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 1, and MATE2-K and an inhibitor of OCT1, OCT2, and MATE1; as a consequence, corresponding clinical drug-drug interaction studies were performed and confirmed the absence of relevant interactions with substrates or inhibitors of these transporters. SIGNIFICANCE STATEMENT: Imeglimin is absorbed through a passive and active mechanism, which can be saturated. It is rapidly and largely distributed to internal organs and mainly excreted unchanged in urine. It is poorly metabolized and has no cytochrome P450 inhibition or induction potential. Imeglimin is a substrate of MATE2-K and also a substrate and an inhibitor of OCT1, OCT2, and MATE1 transporters; however, there are no clinically significant interactions when imeglimin is coadministered with either a substrate or an inhibitor of these transporters.
Asunto(s)
Hipoglucemiantes/farmacocinética , Triazinas/farmacocinética , Administración Intravenosa , Administración Oral , Adulto , Animales , Células CACO-2 , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Perros , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Femenino , Células HEK293 , Humanos , Hipoglucemiantes/administración & dosificación , Absorción Intestinal/efectos de los fármacos , Masculino , Persona de Mediana Edad , Proteínas de Transporte de Catión Orgánico/agonistas , Proteínas de Transporte de Catión Orgánico/antagonistas & inhibidores , Proteínas de Transporte de Catión Orgánico/metabolismo , Ratas , Triazinas/administración & dosificaciónRESUMEN
BACKGROUND: Ponazuril is used for the treatment of equine protozoal myeloencephalitis (EPM). Coadministration of ponazuril with oil could result in higher serum and cerebrospinal fluid (CSF) concentrations of ponazuril. HYPOTHESIS: Coadministration of corn oil will result in higher serum and CSF concentrations of ponazuril than when ponazuril is administered alone. ANIMALS: Ten resident university-owned adult horses of either sex and >2 years of age. METHODS: Cohort study. Ponazuril oral paste (5 mg/kg BW; ponazuril treatment group (PON); n = 5), or ponazuril oral paste (5 mg/kg BW; ponazuril and oil treatment group (PONOIL; n = 5) coadministered with 2 oz of corn oil q24h for 21 days. Horses were treated once daily, for 21 days. Blood was collected on days 0, 7, 14, and 21 before dosing. In addition, CSF was collected on days 1, 7, 14, and 21. The concentration of ponazuril was determined in serum and CSF and results compared using repeated measures ANOVA. RESULTS: Coadministration of ponazuril with 2 oz of corn oil resulted in higher concentrations of ponazuril in serum (at steady state) than that found in horses given ponazuril alone (6.2 ± 0.9 mg/L versus 4.5 ± 1.0 mg/L; P = .004) (mean ± 1 SD). Cerebrospinal fluid concentrations of ponazuril were also greater in horses that received ponazuril and oil (0.213 mg/L ± 0.04 versus 0.162 ± 0.04 mg/L) (P = .03). CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that coadministration of corn oil with ponazuril might enhance the effectiveness of treatment with ponazuril.
Asunto(s)
Antiprotozoarios/farmacocinética , Aceite de Maíz/administración & dosificación , Triazinas/administración & dosificación , Triazinas/farmacocinética , Administración Oral , Animales , Antiprotozoarios/administración & dosificación , Antiprotozoarios/sangre , Antiprotozoarios/líquido cefalorraquídeo , Estudios de Cohortes , Femenino , Caballos , Masculino , Triazinas/sangre , Triazinas/líquido cefalorraquídeoRESUMEN
This work represents the first reporting of a comprehensive bioanalytical GLP methodology detailing the mass spectrometric quantitation of PF-05212384 dosed as a targeted polymeric encapsulated nanoparticle (PF-07034663) to monkeys. Polymeric nanoparticles are a type of drug formulation that enables the sustained release of an active therapeutic agent (payload) for targeted delivery to specific sites of action such as cancer cells. Through the careful design and engineering of the nanoparticle formulation, it is possible to improve the biodistribution and safety of a given therapeutic payload in circulation. However, the bioanalysis of nanoparticles is challenging due to the complexity of the nanoparticle drug formulation itself and the number of pharmacokinetic end points needed to characterize the in vivo exposure of the nanoparticles. Gedatolisib, also known as PF-05212384, was reformulated as an encapsulated targeted polymeric nanoparticle. The bioanalytical assays were validated to quantitate both total and released PF-05212384 derived from the encapsulated nanoparticle (PF-07034663). Assay performance calculated from quality control samples in three batch runs demonstrated intraday precision and accuracy within 10.3 and 12.2%, respectively, and interday precision and accuracy within 9.1 and 8.5%, respectively. This method leveraged automation to ease the burden of a laborious and complicated sample pretreatment and extraction procedure. The automated method was used to support a preclinical safety study in monkeys in which both released and total PF-05212384 concentrations were determined in over 1600 monkey plasma study samples via LC-MS/MS.
Asunto(s)
Morfolinas/administración & dosificación , Nanopartículas/análisis , Polímeros/química , Triazinas/administración & dosificación , Animales , Cromatografía Liquida/métodos , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Evaluación Preclínica de Medicamentos , Haplorrinos , Humanos , Morfolinas/farmacocinética , Nanopartículas/química , Nanopartículas/uso terapéutico , Polímeros/uso terapéutico , Inhibidores de Proteínas Quinasas/administración & dosificación , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem/métodos , Distribución Tisular , Triazinas/farmacocinéticaRESUMEN
Savolitinib is a novel small-molecule selective cMet inhibitor. This work characterized its pharmacokinetics in preclinical phase, established the preclinical relationships between PK, cMet modulation and anti-tumor efficacy. In vitro and in vivo animal studies were performed for PK characterization. Savolitinib showed good absorption, moderate tissue distribution, low to intermediate clearance, and low accumulation. Hepatic oxidative metabolism followed by urinary and biliary excretions was the major elimination pathway. Based on preclinical PK data, human PK profiles were predicted using empirical methods. Pharmacodynamic studies for evaluating cMet inhibition and anti-tumor efficacy were conducted in nude mice bearing Hs746t xenograft. PK/PD models were built to link the PD measurements to nude mouse PK. The established integrated preclinical PK/PD model contained a two-compartment non-linear PK model, a biomarker link model and a tumor growth transit model. The IC50 of cMet inhibition and the concentration achieving half of the maximal Hs746t tumor reduction by savolitinib were equal to 12.5 and 3.7â¯nM (free drug), respectively. Based on the predicted human PK data, as well as the established PK/PD model in nude mouse, the human PD (cMet inhibition) profiles were also simulated. This research supported clinical development of savolitinib. Understanding the preclinical PK/PD relationship of savolitinib provides translational insights into the cMet-targeted drug development.
Asunto(s)
Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/farmacocinética , Pirazinas/farmacología , Pirazinas/farmacocinética , Triazinas/farmacología , Triazinas/farmacocinética , Animales , Células CACO-2 , Línea Celular Tumoral , Evaluación Preclínica de Medicamentos/métodos , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Ratones Desnudos , Modelos Biológicos , Proteínas Proto-Oncogénicas c-met/metabolismo , Ratas , Ensayos Antitumor por Modelo de Xenoinjerto/métodosRESUMEN
BACKGROUND: Astragalosidic acid (LS-102) is a new water-soluble derivative of astragaloside IV - a major effective component isolated from the Chinese herb Astragali Radix. Our previous study showed that LS-102 exhibited potent cardiovascular activity. PURPOSE: The objective of this study was to investigate the pharmacokinetic properties of LS-102 after single-dose, oral administration in beagle dogs by developing and validating an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method. METHOD AND RESULT: The chromatographic separation was performed on a Acquity HSS C18 column (100â¯mmâ¯×â¯2.1â¯mm, 1.8⯵m) by a gradient elution using a mobile phase consisting of water and acetonitrile at a flow rate of 0.35â¯ml/min. The analytes were detected with a triple quadrupole tandem mass spectrometry in multiple reaction monitoring mode. Method validation revealed a wide linearity over the range of 2.0-10,000â¯ng/ml together with satisfactory intra- and inter-day precision, accuracy, and recovery. Stability testing showed that LS-102 spiked into dog plasma was stable for 4â¯h at room temperature, for up to 2 weeks at -80⯰C, and during three freeze-thaw cycles. The method was effectively and successfully applied to the pharmacokinetics of LS-102 after oral administration (5, 10 and 20â¯mg/kg) to beagle dogs. Peak plasma concentrations are attained within approximately 2â¯h after oral administration with a half-life ranging from 1.55â¯h to 4.49â¯h. The plasma concentration-time curve of LS-102 after oral administration presents the phenomenon of a double-peak absorption phase. The peak concentration and area under the concentration-time curve of LS-102 seemed to increase with the increasing doses proportionally, that suggesting linear pharmacokinetics in dogs. Meanwhile, the doxorubicin (Dox)-injured H9c2 cell model was prepared by incubating the cells in 1 µM Dox for 24â¯h. MTT assay and LDH release measurement showed that LS-102 protected against Dox-induced cardiomyocyte death. CONCLUSION: The obtained results may help to guide the further pre-clinical research of LS-102 as a potentially novel cardioprotective agent.
Asunto(s)
Benzoxazoles/sangre , Benzoxazoles/farmacocinética , Cromatografía Liquida/métodos , Saponinas/química , Espectrometría de Masas en Tándem/métodos , Triazinas/sangre , Triazinas/farmacocinética , Triterpenos/química , Administración Oral , Animales , Astragalus propinquus , Benzoxazoles/administración & dosificación , Línea Celular , Cromatografía Líquida de Alta Presión/métodos , Perros , Doxorrubicina/efectos adversos , Estabilidad de Medicamentos , Medicamentos Herbarios Chinos/química , Femenino , Semivida , Masculino , Miocitos Cardíacos/efectos de los fármacos , Ratas , Reproducibilidad de los Resultados , Triazinas/administración & dosificaciónRESUMEN
Paullinia cupana-containing preparations are being consumed worldwide for weight reduction. As obesity and epilepsy are common comorbidities and lamotrigine (LTG) is a broad-spectrum antiepileptic drug, it is likely to find epilepsy patients taking P. cupana and LTG simultaneously. Thus, this work aimed to investigate the potential interaction between P. cupana extract and LTG in rats. In a study, rats were orally co-administered with a single-dose of P. cupana extract (821â¯mg/kg) and LTG (10â¯mg/kg). In another study, rats were orally pre-treated for 14 days with P. cupana extract (821â¯mg/kg/day) receiving LTG (10â¯mg/kg, p.o.) on the 15th day. Rats of the respective control groups received the corresponding volume of the extract vehicle. LTG concentrations were determined at several post-dose time-points and submitted to a non-compartmental pharmacokinetic analysis. The co-administration of P. cupana and LTG induced a significant reduction of LTG Cmax and AUC0-24 and prolonged the mean residence time. However, no significant effects were observed on LTG pharmacokinetics following a 14-day pre-treatment period with the extract. In this study changes in the body weight of rats and in some biochemical parameters were also evaluated. Overall, the results revealed a pharmacokinetic-based herb-drug interaction between P. cupana extract and LTG, mainly after their co-administration.
Asunto(s)
Anticonvulsivantes/farmacocinética , Tracto Gastrointestinal/efectos de los fármacos , Interacciones de Hierba-Droga , Paullinia/química , Extractos Vegetales/administración & dosificación , Triazinas/farmacocinética , Animales , Anticonvulsivantes/administración & dosificación , Tracto Gastrointestinal/metabolismo , Lamotrigina , Masculino , Extractos Vegetales/metabolismo , Ratas , Ratas Wistar , Triazinas/administración & dosificaciónRESUMEN
The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)pyridine (MPEP - a selective antagonist for the glutamate metabotropic receptor subtype mGluR5) on the protective action of some novel antiepileptic drugs (lamotrigine, oxcarbazepine, pregabalin and topiramate) against maximal electroshock-induced seizures in mice. Brain concentrations of antiepileptic drugs were measured to determine whether MPEP altered pharmacokinetics of antiepileptic drugs. Intraperitoneal injection of 1.5 and 2mg/kg of MPEP significantly elevated the threshold for electroconvulsions in mice, whereas MPEP at a dose of 1mg/kg considerably enhanced the anticonvulsant activity of pregabalin and topiramate, but not that of lamotrigine or oxcarbazepine in the maximal electroshock-induced seizures in mice. Pharmacokinetic results revealed that MPEP (1mg/kg) did not alter total brain concentrations of pregabalin and topiramate, and the observed effect in the mouse maximal electroshock seizure model was pharmacodynamic in nature. Collectively, our preclinical data suggest that MPEP may be a safe and beneficial adjunct to the therapeutic effects of antiepileptic drugs in human patients.
Asunto(s)
Anticonvulsivantes/farmacología , Encéfalo/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Piridinas/farmacología , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/farmacocinética , Encéfalo/metabolismo , Carbamazepina/análogos & derivados , Carbamazepina/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Electrochoque , Fructosa/análogos & derivados , Fructosa/farmacocinética , Fructosa/farmacología , Lamotrigina , Masculino , Ratones , Oxcarbazepina , Pregabalina/farmacocinética , Pregabalina/farmacología , Distribución Aleatoria , Receptor del Glutamato Metabotropico 5/antagonistas & inhibidores , Receptor del Glutamato Metabotropico 5/metabolismo , Convulsiones/metabolismo , Topiramato , Triazinas/farmacocinética , Triazinas/farmacologíaRESUMEN
Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis on ligand efficiency and physicochemical properties led to the discovery of compound 44 as a potent, selective and orally active PDE4 inhibitor.
Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Inhibidores de Fosfodiesterasa 4/química , Triazinas/química , Administración Oral , Animales , Sitios de Unión , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 7/antagonistas & inhibidores , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 7/metabolismo , Evaluación Preclínica de Medicamentos , Semivida , Microsomas Hepáticos/metabolismo , Simulación del Acoplamiento Molecular , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/farmacocinética , Estructura Terciaria de Proteína , Ratas , Relación Estructura-Actividad , Triazinas/síntesis química , Triazinas/farmacocinéticaRESUMEN
BACKGROUND: The aim of our research was to evaluate some biochemical changes in blood during lamotrigine (LTG) monotherapy of adult patients with epilepsy, and to check possible associations between typical selenium status parameters and the frequency of seizures. METHODS: The study was performed by examining aspartate aminotransferase (AspAT), alanine aminotransferase (AlaAT), creatinine, ferric reducing ability of plasma (FRAP), serum uric acid (UA), uric-acid-independent FRAP (UAiFRAP), plasma glutathione peroxidase (GPX3), selenoprotein P (SelP), plasma superoxide dismutase (pSOD), 8-hydroxy-2'-deoxyguanosine (8-OHdG) in serum and urine, serum selenium (sSe) and zinc (sZn), in 22 adult patients with epilepsy and 22 healthy controls. Additionally, the levels of LTG were determined in patients. RESULTS: pSOD activity was higher in the study group (5.32±1.24 U/ml) compared with the controls (4.05±0.92 U/ml, p=0.008). No other statistical difference between patients and controls was found. CONCLUSION: Lack of difference in parameters other than SOD, particularly no difference in 8-OHdG concentrations between the patients treated with LTG compared to the control subjects suggests that these patients are at no particular risk of oxidative DNA damage. In patients who are well or moderately well clinically controlled, selenium status parameters (sSe, GPX3, SelP) are not directly connected with the frequency of seizures.
Asunto(s)
Anticonvulsivantes/farmacología , Antioxidantes/metabolismo , Epilepsia/tratamiento farmacológico , Triazinas/farmacología , 8-Hidroxi-2'-Desoxicoguanosina , Adulto , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/uso terapéutico , Estudios de Casos y Controles , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Epilepsia/fisiopatología , Femenino , Humanos , Lamotrigina , Masculino , Selenio/metabolismo , Superóxido Dismutasa/metabolismo , Triazinas/farmacocinética , Triazinas/uso terapéutico , Adulto JovenRESUMEN
PURPOSE: Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts. METHODS: In vitro studies were conducted in liver and intestinal fractions, plasma and Caco-2 cells to assess the metabolic stability. Pharmacokinetics of brivanib were determined in preclinical species after administration of single intravenous or oral doses of both brivanib and brivanib alaninate. The antitumor efficacy was assessed at equimolar doses in nude mice bearing human tumor xenografts. Human efficacious dose was predicted based on projected human pharmacokinetic parameters and exposure at efficacious doses in the mouse efficacy models. RESULTS: In vitro and in vivo studies indicated that brivanib alaninate was efficiently converted to brivanib. Brivanib showed good brain penetration in rats consistent with its high intrinsic permeability and lack of active efflux in Caco-2 cells. The oral bioavailability of brivanib varied among species (22-88%) and showed dissolution rate-limited absorption even when combined with organic co-solvents. Administration of brivanib as brivanib alaninate allowed completely aqueous vehicles, and an improvement in the oral bioavailability (55-97%) was observed. The clearance of brivanib in humans is anticipated to be low to intermediate (hepatic extraction ratio < 0.7), while its volume of distribution is expected to be high. The minimum efficacious dose of brivanib alaninate was determined to be 60 mg/kg per day. CONCLUSIONS: Brivanib alaninate is rapidly and efficiently converted to the parent, brivanib, as demonstrated both in vitro and in vivo and offers an excellent mode to deliver brivanib orally.
Asunto(s)
Alanina/análogos & derivados , Antineoplásicos/farmacocinética , Pirroles/farmacocinética , Triazinas/farmacocinética , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Administración Oral , Alanina/farmacocinética , Alanina/farmacología , Animales , Antineoplásicos/farmacología , Disponibilidad Biológica , Encéfalo/metabolismo , Células CACO-2 , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Inyecciones Intravenosas , Macaca fascicularis , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Profármacos , Pirroles/farmacología , Ratas , Solubilidad , Distribución Tisular , Triazinas/farmacología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
PURPOSE: To compare oxygen dependence and tissue transport properties of a new hypoxia-activated prodrug, PR-104A, with tirapazamine, and to evaluate the implications for antitumor activity when combined with radiotherapy. METHODS AND MATERIALS: Oxygen dependence of cytotoxicity was measured by clonogenic assay in SiHa cell suspensions. Tissue transport parameters were determined using SiHa multicellular layers. Spatially resolved pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to predict cell killing in SiHa tumors and tested by clonogenic assay 18 h after treatment with the corresponding phosphate ester, PR-104. RESULTS: The K-value (oxygen concentration to halve cytotoxic potency) of PR-104A was 0.126 +/- 0.021 microM (10-fold lower than tirapazamine at 1.30 +/- 0.28 microM). The diffusion coefficient of PR-104A in multicellular layers (4.42 +/- 0.15 x 10(-7) cm2 s(-1)) was lower than that of tirapazamine (1.30 +/- 0.05 x 10(-6) cm2 s(-1)) but PK modeling predicted better penetration to hypoxic cells in tumors because of its slower metabolism. The tirapazamine PK/PD model successfully predicted the measured activity in combination with single-dose radiation against SiHa tumors, and the PR-104A model underpredicted the activity, which was greater for PR-104 than for tirapazamine (at equivalent host toxicity) both with radiation and as a single agent. CONCLUSION: PR-104/PR-104A has different PK/PD properties from tirapazamine and superior activity with single-dose radiotherapy against SiHa xenografts. We have inferred that PR-104A is better able to kill cells at intermediate partial pressure of oxygen in tumors than implied by the PK/PD model, most likely because of a bystander effect resulting from diffusion of its activated metabolites from severely hypoxic zones.
Asunto(s)
Antineoplásicos/farmacocinética , Hipoxia de la Célula/fisiología , Compuestos de Mostaza Nitrogenada/farmacocinética , Oxígeno/fisiología , Profármacos/farmacocinética , Triazinas/farmacocinética , Animales , Transporte Biológico , Evaluación Preclínica de Medicamentos , Humanos , Ratones , Ratones Desnudos , Modelos Biológicos , Presión Parcial , Fármacos Sensibilizantes a Radiaciones/farmacocinética , Tirapazamina , Células Tumorales CultivadasRESUMEN
PURPOSE: Serotonin1A (5-HT1A) receptors exist in high- and low-affinity states, and agonist ligands bind preferentially to the high-affinity state of the receptor and provide a measure of functional 5-HT1A receptors. Although the antagonist tracers are established PET ligands in clinical studies, a successful 5-HT1A receptor agonist radiotracer in living brain has not been reported. [11C]MPT, our first-generation agonist radiotracer, shows in vivo specificity in baboons; however, its utility is limited owing to slow washout and immeasurable plasma free fraction. Hence we performed structure-activity relationship studies of MPT to optimize a radiotracer that will permit valid quantification of 5-HT1A receptor binding. We now report the synthesis and evaluation of [11C]MMP as an agonist PET tracer for 5-HT1A receptors in baboons. METHODS: In vitro binding assays were performed in bovine hippocampal membranes and membranes of CHO cells expressing 5-HT1A receptors. [11C] labeling of MMP was performed by reacting desmethyl-MMP with [11C]CH(3)OTf. In vivo studies were performed in baboons, and blocking studies were conducted by pretreatment with 5-HT1A receptor ligands WAY-100635 and (+/-)-8-OH-DPAT. RESULTS: MMP is a selective 5-HT1A receptor agonist (Ki 0.15 nM). Radiosynthesis of [11C]MMP was achieved in 30 +/- 5% (n = 15) yield at EOS with a specific activity of 2,600 +/- 500 Ci/mmol (n = 12). PET studies in baboons demonstrated specific binding of [11C]MMP to 5-HT1A receptor-enriched brain regions, as confirmed by blockade with WAY-100635 and (+/-)-8-OH-DPAT. CONCLUSION: We identified [11C]MMP as an optimal agonist PET tracer that shows quantifiable, specific binding in vivo to 5-HT1A receptors in baboons.
Asunto(s)
Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Piperazinas/farmacocinética , Tomografía de Emisión de Positrones/métodos , Agonistas del Receptor de Serotonina 5-HT1 , Triazinas/farmacocinética , Animales , Evaluación Preclínica de Medicamentos , Humanos , Marcaje Isotópico/métodos , Papio , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Distribución TisularRESUMEN
Large-scale screening has led to the identification of several experimental compounds that have very potent intrinsic activity against coccidia, but the lack of translation to in vivo efficacy has been a major hurdle in developing such leads into effective new drugs. We developed methods to explore the impact of oral availability and appropriate distribution in tissue, both of which are potentially important factors in the expression of activity in vivo. For the compounds that we examined, neither oral absorption nor distribution to the site of infection appeared to be the critical barrier to in vivo expression of intrinsic anticoccidial activity. Elucidation of the nature of additional factors that might be involved could assist greatly in the identification of useful new anticoccidial agents.
Asunto(s)
Coccidiosis/tratamiento farmacológico , Coccidiostáticos/uso terapéutico , Decoquinato/uso terapéutico , Eimeria tenella/efectos de los fármacos , Quinazolinas/uso terapéutico , Sulfonamidas/uso terapéutico , Triazinas/uso terapéutico , Administración Oral , Animales , Pollos , Coccidiostáticos/administración & dosificación , Coccidiostáticos/farmacocinética , Decoquinato/administración & dosificación , Decoquinato/farmacocinética , Evaluación Preclínica de Medicamentos , Bombas de Infusión , Quinazolinas/administración & dosificación , Quinazolinas/farmacocinética , Quinazolinonas , Sulfonamidas/administración & dosificación , Sulfonamidas/farmacocinética , Distribución Tisular , Triazinas/administración & dosificación , Triazinas/farmacocinéticaRESUMEN
Recently, there has been an increase in the research devoted to the study of investigational antiepileptic medications. This has led to extensive clinical trials of several new compounds. This review focuses on four of these antiepileptic medications in development: felbamate, gabapentin, lamotrigine, and vigabatrin. Each has a unique mechanism of action and great potential for the treatment of epilepsy.
Asunto(s)
Aminas , Anticonvulsivantes , Ácidos Ciclohexanocarboxílicos , Drogas en Investigación , Ácido gamma-Aminobutírico , Acetatos/farmacocinética , Acetatos/farmacología , Aminocaproatos/farmacocinética , Aminocaproatos/farmacología , Animales , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/farmacología , Química Farmacéutica , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Drogas en Investigación/farmacocinética , Drogas en Investigación/farmacología , Felbamato , Gabapentina , Humanos , Lamotrigina , Fenilcarbamatos , Glicoles de Propileno/farmacocinética , Glicoles de Propileno/farmacología , Triazinas/farmacocinética , Triazinas/farmacología , VigabatrinRESUMEN
A thermospray liquid chromatographic-mass spectrometric (TSP LC-MS) method has been developed for the analysis of the herbicide metribuzin and its three major metabolites in plant tissue. Metribuzin and its metabolites exhibited widely varying sensitivities in positive-ion TSP, with metribuzin being the most sensitive and deaminated diketo metribuzin being the least sensitive. All four compounds of interest were detected in an extract of a soybean plant which had been treated with metribuzin.